# Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

> **NCT00458835** · PHASE4 · COMPLETED · sponsor: **Covis Pharma S.à.r.l.** · enrollment: 30 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** Ciclesonide

## Key facts

- **NCT ID:** NCT00458835
- **Lead sponsor:** Covis Pharma S.à.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458835, "Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00458835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*